Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV

Lena van der Wekken-Pas; Fabian Weiss; Charlotte Simon-Zuber; Rena Sebisch; Carmen Wiese; Elisabeth van Leeuwen; David Burger; Angela Colbers

doi:10.1093/cid/ciae242

Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV

Clin Infect Dis. 2024 May 3:ciae242. doi: 10.1093/cid/ciae242. Online ahead of print.

Authors

Lena van der Wekken-Pas¹, Fabian Weiss², Charlotte Simon-Zuber², Rena Sebisch², Carmen Wiese³, Elisabeth van Leeuwen⁴, David Burger¹, Angela Colbers¹

Affiliations

¹ Radboud university medical center, department of pharmacy, Radboud Institute for Medical Innovations (RIMI), Nijmegen, the Netherlands.
² Department of Obstetrics and Gynecology, LMU university hospital, LMU Munich, Germany.
³ MVZ München am Goetheplatz, Munich, Germany.
⁴ Amsterdam university medical center, department of gynecology, Amsterdam, the Netherlands.

PMID: 38703388
DOI: 10.1093/cid/ciae242

Abstract

This case report describes bimonthly LAI CAB/RPV prior to and throughout pregnancy. CAB concentration was comparable to non-pregnant individuals, RPV was 70-75% lower. No virologic failure orvertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly CAB/RPV LAI may not be suitable for pregnant women and monitoring of exposed infants is warranted.

Keywords: HIV; cabotegravir; long acting injectables; pregnancy; rilpivirine.